tumor necrosis factor inhibitors

Dr. Jim Woody, CEO, 180 Life Sciences, Working to Meet Unmet Needs in Pain and Inflammation

Rob DillardRheumatology | April 28, 2023

DocWire News recently spoke with Dr. Jim Woody, CEO of 180 Life Sciences, a company that develops new treatments for ...

Do Autoimmune Diseases Impact COVID-19 Outcomes?

Kaitlyn D’OnofrioCOVID-19 | April 25, 2023

Patients with autoimmune diseases may be at a greater risk for COVID-19, possibly due to glucocorticoid use, while ...

Infliximab and Golimumab: Are These Anti-TNF Agents Suitable for Long-Term RA Treatment?

Kaitlyn D’OnofrioRheumatoid Arthritis | April 25, 2023

A long-term registry study evaluating the effectiveness of infliximab, golimumab, and intravenous (IV) golimumab in ...

PTSD, Anxiety, Depression Increase RA Medication Discontinuation Risk

Kaitlyn D’OnofrioDepression | April 25, 2023

Veterans with posttraumatic stress disorder (PTSD), anxiety, and depression on medication for rheumatoid arthritis (RA) ...

Rheum Round-up: Sarilumab Flops in COVID-19, RA TNFi Termination and Body Weight, and more

Kaitlyn D’OnofrioRheumatology | April 25, 2023

Here are the top stories recently covered by DocWire News in the rheumatology section. In this edition, read about ...

Overweight And Underweight Are Both Risk Factors for TNFi Treatment Discontinuation in RA

Kaitlyn D’OnofrioRheumatoid Arthritis | April 25, 2023

Rheumatoid arthritis (RA) patients with either a low or high body mass index (BMI) are more likely than normal weight RA ...

NSAIDs, DMARDs May Not Increase Hospitalization Risk in COVID-19 Patients

Kaitlyn D’OnofrioCOVID-19 | April 25, 2023

The use of non-steroidal anti-inflammatory drugs (NSAIDs) and conventional disease-modifying antirheumatic drugs ...

Triple Therapy Versus TNFi Plus Methotrexate for Rheumatoid Arthritis: A Real-World Treatment Comparison

Kaitlyn D’OnofrioRheumatoid Arthritis | April 25, 2023

A recent study compared real-world outcomes between rheumatoid arthritis (RA) patients treated with triple therapy ...

Do Outcomes Largely Differ in Very Early Rheumatoid Arthritis Treated with First-line Etanercept Plus Methotrexate versus Treat-to-Target Methotrexate?

Kaitlyn D’OnofrioRheumatoid Arthritis | April 25, 2023

A study compared superiority outcomes in very early rheumatoid arthritis (RA) treated with first-line etanercept plus ...

Anti-TNFα Therapy Not Linked to Recurrent or New Cancer in Patients with Previous Cancer

Kaitlyn D’OnofrioOncology | April 25, 2023

A new study observed no correlation between anti-tumor necrosis factor-α (Anti-TNFα) therapy and recurrent or new ...

Serious Infection Risk in Psoriasis and PsA Patients Using Biologics

DocWire News EditorsPsoriasis | April 25, 2023

A recent retrospective cohort analysis explored the association between risk of serious infection and initiation of ...

Suboptimal Drug Concentrations May Predict Anti-TNF Treatment Failure for Crohn’s

DocWire News EditorsGastroenterology | April 25, 2023

Low drug response may be a key predictor of anti-TNF treatment failure in patients with Crohn’s disease, according to ...

Rheum in Review: Tocilizumab and Malignancy, Vitamin B and Hip Fracture Risk, Rituximab for RA Prevention, and More

Kaitlyn D’OnofrioRheumatology | April 25, 2023

Here are the top stories covered by DocWire News this week in the Rheumatology section. In this edition, learn the ...

Rheum Roundup: Switching PsA Medication, Exercise for RA, AI for Hip Fracture, and More

Kaitlyn D’OnofrioRheumatology | April 25, 2023

Patients taking a tumor necrosis factor inhibitor (TNFi) for their psoriatic arthritis (PsA) who are considering ...

Treatment Outcomes: Should PsA Patients Switch Their TNFi or Change to non-TNFi?

Kaitlyn D’OnofrioPsoriatic Arthritis | April 25, 2023

Psoriatic arthritis (PsA) patients being treated with a tumor necrosis factor inhibitor (TNFi) may have a reduced ...

Rheumatology Week in Review: Drug Price Comparisons, Fast Facts on Ankylosing Spondylitis, New Psoriasis Treatment

Kaitlyn D’OnofrioRheumatology | April 25, 2023

Here are the top stories covered by DocWire News this week in the Rheumatology section. In this edition, learn about a ...

How Does Anti-TNF Withdrawal Affect Ankylosing Spondylitis?

Kaitlyn D’OnofrioRheumatology | April 25, 2023

A recent study evaluated outcomes for patients with ankylosing spondylitis (AS) in clinical remission being treated with ...

Rheum in Review: Medication, Mobility, and Mental Health Connections

Kaitlyn D’OnofrioRheumatology | April 25, 2023

Here are the top stories covered by DocWire News this week in the Rheumatology section. In this edition, learn about ...

High Dose Tofacitinib Increases Mortality Risk in RA Patients

Kaitlyn D’OnofrioRheumatoid Arthritis | September 6, 2023

Rheumatoid arthritis (RA) patients taking a 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR) may have an ...

TNFi Use Not Tied to Joint Replacement

Kaitlyn D’OnofrioOrthopedics | April 25, 2023

A study found that the use of a tumor necrosis factor inhibitor (TNFi) among rheumatoid arthritis (RA) patients was not ...